The European Research Area Act 2026 is a planned EU regulation that will attach binding legal mechanisms to the long-standing target of investing 3% of GDP in research and development. Announced in the Competitiveness Compass for the EU (COM(2025) 30, 29 January 2025) and built on the ERA Policy Agenda 2025–2027, the Act moves the EU’s R&D investment ambition from a voluntary benchmark to a governed, monitored commitment. A Commission proposal is expected before summer 2026, following a Call for Evidence, a public consultation, and a European Parliament resolution adopted on 10 March 2026.
The European Research Area (ERA) is the European Commission’s framework for a single, borderless market for research, innovation and technology across the EU, in which Member States align research policies, funding, and researcher mobility. The ERA Act is the first attempt to give this framework binding legal force.
- What is the European Research Area Act?
- Why is the Commission legislating in 2026, and what is the timeline?
- How will the Act attach legal mechanisms to the 3% GDP R&D target?
- What does this mean for Horizon Europe associated countries?
- Answer-first Q&A
- Implications for research administrators and institutions
- Outlook: what happens next
What is the European Research Area Act?
The European Research Area Act is the European Commission’s forthcoming legislative instrument to give the ERA — previously a policy framework built on non-binding recommendations — a coherent, enforceable legal basis. It follows the Pact for Research and Innovation in Europe, a Council Recommendation adopted in November 2021 that set common values and priority areas but carried no binding obligations.
According to the Commission’s own ERA Act platform, the initiative responds to “fragmented regulatory frameworks, uneven R&D investment, and barriers to knowledge sharing” across the EU research and innovation ecosystem. Reporting from Science|Business and civil-society coalitions describes the emerging proposal around four pillars:
- Safeguarding the freedom of scientific research through dedicated legislation
- Establishing a strong, binding and coherent ERA governance structure
- Embedding the 3% R&D investment target and improving alignment of public and private funding with EU strategic priorities
- Enhancing researcher circulation, careers and working conditions, including mobility, gender equality and knowledge security
The Act is explicitly linked to the parallel European Innovation Act, which will address market-side barriers to commercialising research, and to the Commission’s “Choose Europe for Science” agenda aimed at attracting global research talent.
Why is the Commission legislating in 2026, and what is the timeline?
The Commission originally scheduled the ERA Act for 2027 but brought it forward after the Competitiveness Compass identified research and innovation fragmentation as a drag on EU competitiveness. Ekaterina Zaharieva, the EU Commissioner for Startups, Research and Innovation, described the planned Act in September 2025 as “ambitious but realistic,” signalling that the Commission intends genuine legal obligations rather than another voluntary agenda.
The process has moved through several concrete, dated milestones:
| Milestone | Date |
|---|---|
| Competitiveness Compass for the EU, COM(2025) 30 | 29 January 2025 |
| ERA Act Call for Evidence opens | 6 August 2025 |
| Call for Evidence closes (178 contributions, 29 countries) | 10 September 2025 |
| Public consultation questionnaire closes | 23 January 2026 |
| Commission publishes Call for Evidence analysis report | 4 February 2026 |
| European Parliament resolution on the upcoming ERA Act | 10 March 2026 |
| Commission legislative proposal (expected) | Before summer 2026 |
The Call for Evidence alone drew 178 contributions from 29 countries, according to the Commission’s published analysis — a scale of stakeholder engagement that indicates the Act is being treated as a substantive legislative undertaking, not a policy communication.
How will the Act attach legal mechanisms to the 3% GDP R&D target?
The 3%-of-GDP R&D investment target is not new. It dates to the Barcelona European Council of March 2002, which set the goal of raising EU R&D spending to 3% of GDP by 2010, with two-thirds expected from private investment and one-third from public funding. The target was carried forward through the Europe 2020 strategy and, most recently, the ERA Policy Agenda 2025–2027, but EU average R&D intensity has persistently undershot it for two decades.
What changes under the ERA Act is enforceability. Rather than restating the 3% ambition as an aspiration, the Act is expected to embed it within binding governance mechanisms — monitoring obligations, alignment requirements between EU and national funding instruments, and reporting duties tied to Member States’ national reform and investment plans. This shifts the target from a statistic tracked in Commission reports to a legal reference point Member States must account against.
This is a materially different approach from the Pact for Research and Innovation in Europe, which asked Member States to “endeavour” toward the target with no compliance architecture. Research administrators tracking national R&D budget lines should expect the ERA Act to introduce the kind of structured reporting cycle already familiar from Horizon Europe’s own performance monitoring.
What does this mean for Horizon Europe associated countries?
Horizon Europe associated countries — including Norway, Iceland, Israel, Ukraine, and the United Kingdom (associated from 1 January 2024) — participate in EU framework programme funding without being EU Member States. The ERA Act, as an EU legislative act, is expected to bind Member States directly; association agreements do not automatically extend domestic investment-target obligations to associated third countries.
This creates a practical asymmetry research offices should track: associated countries’ researchers and institutions can compete for Horizon Europe funding and access ERA-linked infrastructure and mobility schemes, but their governments are unlikely to face the same binding 3% reporting duties as EU Member States. Institutions in associated countries should monitor whether the eventual Act text extends any governance or reporting provisions to association agreements, as this has not yet been confirmed in any published Commission text.
Answer-first Q&A
What is the European Research Area?
The European Research Area (ERA) is the European Commission’s framework for a single, borderless market for research, innovation and technology across the EU. It coordinates national research policies and systems and supports free movement of researchers, scientific knowledge, and innovation between Member States.
What are the priorities of the European Research Area?
ERA priorities include more effective national research systems, optimal transnational cooperation, an open labour market for researchers, gender equality in research, and improved circulation of scientific knowledge. The ERA Policy Agenda 2025–2027 operationalises these priorities into time-bound actions for Member States.
What is the 3% GDP research and development investment target?
The 3% GDP R&D target commits the EU to raising combined public and private research spending to 3% of GDP, split roughly two-thirds private and one-third public. Set at the 2002 Barcelona European Council, it remains unmet EU-wide and is the ERA Act’s central binding-mechanism focus.
Will the ERA Act apply to Horizon Europe associated countries?
The ERA Act is expected to bind EU Member States as an EU legislative act; Horizon Europe association agreements do not automatically extend national 3% investment-target obligations to associated countries such as Norway or the UK. Scope for associated countries has not yet been confirmed in a published legal text.
Implications for research administrators and institutions
For institutional research offices, funders, and national research administration bodies, the ERA Act signals a shift toward auditable, comparable national R&D investment reporting. Research administration teams should expect closer alignment between EU-level ERA governance and domestic funding-agency reporting cycles, similar to how Horizon Europe already requires structured performance data from participating institutions.
Practical preparation steps include:
- Mapping current national R&D investment reporting against the ERA Policy Agenda 2025–2027 actions to identify gaps before binding obligations take effect
- Tracking the Commission’s legislative proposal, expected before summer 2026, for confirmed governance and monitoring mechanisms
- Reviewing whether institutional funding applications reference ERA priorities such as researcher mobility, open science, and gender equality, since these are likely compliance touchpoints under the Act
Institutions with dedicated research administration capacity are better positioned to respond quickly once the proposal text and accompanying governance requirements are published.
Outlook: what happens next
The Commission’s legislative proposal is expected before summer 2026, after which the ERA Act will follow the ordinary EU legislative procedure through the European Parliament and Council — a process that typically takes 18 to 24 months before final adoption and Member State transposition. Research administrators, funders, and institutional leaders should treat the current pre-proposal period as the window to influence scope, particularly regarding associated-country coverage and the specific reporting mechanisms attached to the 3% target, rather than waiting for a finalised text to begin preparation.